Trial Profile
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary) ; Tocilizumab (Primary)
- Indications COVID 2019 infections; Pneumonia
- Focus Therapeutic Use
- 01 Jan 2021 Results published in the Biomedicine and Pharmacotherapy
- 26 Mar 2020 New trial record